Redhill Historical Income Statement

RDHL Stock  USD 0.53  0.02  3.92%   
Historical analysis of Redhill Biopharma income statement accounts such as Research Development of 8 M, Total Operating Expenses of 44.4 M, Total Revenue of 74.6 M or Gross Profit of 34.4 M can show how well Redhill Biopharma performed in making a profits. Evaluating Redhill Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Redhill Biopharma's future profits or losses.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Redhill Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Redhill Biopharma is a good buy for the upcoming year.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.

About Redhill Income Statement Analysis

Redhill Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Redhill Biopharma shareholders. The income statement also shows Redhill investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Redhill Biopharma Income Statement Chart

Redhill Biopharma Income Statement is one of the three primary financial statements used for reporting Redhill's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Redhill Biopharma revenue and expense. Redhill Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Redhill Biopharma's Gross Profit is quite stable compared to the past year. Cost Of Revenue is expected to rise to about 40.3 M this year, although the value of EBIT will most likely fall to (40.5 M).

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Redhill Biopharma. It is also known as Redhill Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most accounts from Redhill Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Redhill Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.At this time, Redhill Biopharma's Gross Profit is quite stable compared to the past year. Cost Of Revenue is expected to rise to about 40.3 M this year, although the value of EBIT will most likely fall to (40.5 M).

Redhill Biopharma income statement Correlations

0.70.940.95-0.77-0.80.13-0.690.87-0.9-0.81-0.90.010.960.830.85-0.91-0.74-0.830.260.99
0.70.870.73-0.36-0.39-0.27-0.290.53-0.64-0.96-0.48-0.670.840.750.71-0.67-0.98-0.670.060.64
0.940.870.92-0.66-0.690.04-0.580.78-0.86-0.91-0.78-0.290.960.830.83-0.87-0.89-0.820.060.91
0.950.730.92-0.87-0.890.27-0.820.93-0.97-0.81-0.94-0.050.960.830.82-0.98-0.76-0.770.360.93
-0.77-0.36-0.66-0.871.0-0.660.99-0.940.940.450.96-0.27-0.71-0.57-0.60.930.420.52-0.38-0.76
-0.8-0.39-0.69-0.891.0-0.620.99-0.950.950.490.98-0.26-0.74-0.6-0.630.940.450.54-0.4-0.79
0.13-0.270.040.27-0.66-0.62-0.710.47-0.390.25-0.470.490.02-0.140.07-0.360.24-0.020.040.16
-0.69-0.29-0.58-0.820.990.99-0.71-0.910.90.370.93-0.29-0.63-0.49-0.520.880.350.42-0.41-0.68
0.870.530.780.93-0.94-0.950.47-0.91-0.97-0.64-0.970.140.840.710.7-0.96-0.59-0.690.340.89
-0.9-0.64-0.86-0.970.940.95-0.390.9-0.970.730.97-0.04-0.9-0.75-0.770.990.70.71-0.34-0.89
-0.81-0.96-0.91-0.810.450.490.250.37-0.640.730.610.51-0.91-0.81-0.80.750.980.79-0.14-0.78
-0.9-0.48-0.78-0.940.960.98-0.470.93-0.970.970.61-0.25-0.84-0.7-0.730.970.540.68-0.43-0.9
0.01-0.67-0.29-0.05-0.27-0.260.49-0.290.14-0.040.51-0.25-0.18-0.18-0.120.00.610.060.320.08
0.960.840.960.96-0.71-0.740.02-0.630.84-0.9-0.91-0.84-0.180.890.86-0.91-0.86-0.850.320.93
0.830.750.830.83-0.57-0.6-0.14-0.490.71-0.75-0.81-0.7-0.180.890.55-0.77-0.77-0.70.290.8
0.850.710.830.82-0.6-0.630.07-0.520.7-0.77-0.8-0.73-0.120.860.55-0.78-0.73-0.830.260.84
-0.91-0.67-0.87-0.980.930.94-0.360.88-0.960.990.750.970.0-0.91-0.77-0.780.720.71-0.35-0.9
-0.74-0.98-0.89-0.760.420.450.240.35-0.590.70.980.540.61-0.86-0.77-0.730.720.72-0.06-0.69
-0.83-0.67-0.82-0.770.520.54-0.020.42-0.690.710.790.680.06-0.85-0.7-0.830.710.72-0.09-0.86
0.260.060.060.36-0.38-0.40.04-0.410.34-0.34-0.14-0.430.320.320.290.26-0.35-0.06-0.090.23
0.990.640.910.93-0.76-0.790.16-0.680.89-0.89-0.78-0.90.080.930.80.84-0.9-0.69-0.860.23
Click cells to compare fundamentals

Redhill Biopharma Account Relationship Matchups

Redhill Biopharma income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization2.5M9.0M18.1M8.2M9.5M9.9M
Interest Expense438K12.8M16.6M41.3M47.5M49.9M
Selling General Administrative11.5M25.4M76.6M55.0M63.2M66.4M
Other Operating Expenses49.5M128.0M166.9M104.6M120.3M126.4M
Operating Income(43.2M)(63.7M)(81.1M)(42.8M)(38.6M)(40.5M)
Ebit(43.2M)(63.7M)(81.1M)(42.8M)(38.6M)(40.5M)
Research Development17.4M16.5M29.5M7.3M8.4M8.0M
Ebitda(40.7M)(54.7M)(63M)(34.6M)(31.1M)(32.7M)
Total Operating Expenses47.2M91.2M117.5M71.3M82.0M44.4M
Income Before Tax(42.3M)(76.2M)(97.7M)(71.7M)(64.5M)(61.3M)
Total Other Income Expense Net897K(12.5M)(16.6M)(28.8M)(25.9M)(24.6M)
Net Income(43.6M)(89.0M)(114.3M)(59.2M)(53.3M)(56.0M)
Income Tax Expense1.3M12.8M16.6M(12.4M)(14.3M)(13.6M)
Total Revenue6.3M64.4M85.8M61.8M71.1M74.6M
Gross Profit4.0M27.5M36.4M28.5M32.7M34.4M
Cost Of Revenue2.3M36.9M49.4M33.3M38.3M40.3M
Net Income From Continuing Ops(42.3M)(76.2M)(97.7M)(71.7M)(64.5M)(67.7M)
Net Income Applicable To Common Shares(38.8M)(42.3M)(76.2M)(97.7M)(88.0M)(83.6M)
Net Interest Income5K(12.6M)(16.6M)(41.2M)(37.1M)(35.3M)
Interest Income443K176K51K140K126K190.6K
Selling And Marketing Expenses18.3M49.3M11.4M9.1M10.4M20.6M
Reconciled Depreciation1.2M8.7M18.1M8.2M9.4M6.7M
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Redhill Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Redhill Biopharma's short interest history, or implied volatility extrapolated from Redhill Biopharma options trading.

Currently Active Assets on Macroaxis

When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.
Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Redhill Stock analysis

When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.00)
Revenue Per Share
14.516
Quarterly Revenue Growth
(0.90)
Return On Assets
(0.17)
Return On Equity
(8.84)
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.